Is Contrave a Controlled Substance? The DEA Schedule IV Classification and What It Actually Means for Patients

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Contrave is classified as a Schedule IV controlled substance by the DEA because it contains bupropion, which has recognized but low abuse potential
• Schedule IV status requires special prescribing rules: no automatic refills, prescription expires after 6 months, and interstate transfer restrictions apply
• GLP-1 medications like semaglutide and tirzepatide are NOT controlled substances and face none of these restrictions
• The controlled status creates practical barriers for Contrave patients that don't exist for compounded GLP-1 users, including refill coordination and travel complications

Direct answer (40-60 words)

Yes. Contrave is a Schedule IV controlled substance under the Controlled Substances Act because it contains bupropion, which the DEA classifies as having low but recognized abuse potential. This classification imposes prescribing restrictions including no automatic refills, 6-month prescription expiration, and state-specific dispensing rules that do not apply to GLP-1 medications.

Table of contents

1. The classification: why Contrave is Schedule IV
2. What Schedule IV actually means in practice
3. The bupropion component: why it's controlled when naltrexone isn't
4. Prescribing restrictions that affect Contrave patients
5. How controlled status differs from GLP-1 medications
6. State-by-state variation in controlled substance rules
7. Travel restrictions and what you need to carry
8. The refill coordination problem
9. What most articles get wrong about Contrave's controlled status
10. When controlled status becomes a treatment barrier
11. The abuse potential data: what the evidence actually shows
12. FAQ
13. Sources

The classification: why Contrave is Schedule IV

Contrave (naltrexone/bupropion extended-release) received Schedule IV classification from the Drug Enforcement Administration in September 2014, concurrent with its FDA approval for chronic weight management. The classification stems entirely from the bupropion component.

The DEA schedules drugs into five categories based on abuse potential, accepted medical use, and safety profile. Schedule I drugs (heroin, LSD) have high abuse potential and no accepted medical use. Schedule V drugs (cough preparations with small amounts of codeine) have the lowest abuse potential among controlled substances.

Schedule IV sits in the middle-to-low range. Drugs in this category have:

• Low potential for abuse relative to Schedule III substances
• Currently accepted medical use in the United States
• Limited physical or psychological dependence risk relative to Schedule III

Other Schedule IV drugs include alprazolam (Xanax), diazepam (Valium), zolpidem (Ambien), and tramadol. The category represents medications with legitimate therapeutic value but enough abuse signal to warrant prescribing oversight.

Contrave's Schedule IV placement is not based on the combination formulation. It's based solely on bupropion, which has been Schedule IV since the DEA rescheduled it from uncontrolled status in 2017 after accumulating post-market abuse reports.

Naltrexone, the other component in Contrave, is NOT a controlled substance. It's an opioid antagonist with no abuse potential (it blocks opioid receptors rather than activating them). If Contrave contained only naltrexone, it would not be controlled.

What Schedule IV actually means in practice

The Schedule IV classification triggers specific legal requirements under the Controlled Substances Act and state pharmacy laws. These requirements create friction points that patients often don't anticipate:

Prescription time limits. A Schedule IV prescription expires 6 months from the date written or after 5 refills, whichever comes first. After that window, you need a new prescription even if refills remain. Non-controlled medications don't have federal expiration rules.

No automatic refills. Your pharmacy cannot automatically refill a Schedule IV prescription. You must request each refill, and the pharmacy must verify it's within the legal window. Many chain pharmacies have automated systems that will reject refill requests if you're even one day early.

Written or electronic prescription required. Schedule IV prescriptions can be called in by phone (unlike Schedule II), but most states now require electronic prescribing (e-prescribing) for controlled substances. Paper prescriptions are increasingly rare and subject to additional security requirements.

Transfer restrictions. Federal law allows one-time transfer of Schedule IV prescriptions between pharmacies, but many states impose stricter rules. Some prohibit transfers entirely. Some allow transfers only within the same pharmacy chain. If you switch pharmacies, you often need a new prescription rather than transferring the existing one.

Quantity limits. While federal law doesn't cap Schedule IV quantities, many state laws and insurance formularies impose 30-day supply limits. A 90-day supply, common for maintenance medications, often requires prior authorization or is simply unavailable for controlled substances.

Prescriber registration. Only DEA-registered prescribers can write controlled substance prescriptions. Nurse practitioners and physician assistants can prescribe Schedule IV drugs in most states, but their authority varies by state and requires separate DEA registration.

These rules exist for diversion control, not patient safety. The restrictions aim to prevent pills from reaching non-patients, not to protect you from the medication itself.

The bupropion component: why it's controlled when naltrexone isn't

Bupropion became a controlled substance in 2017 after the DEA documented increasing abuse patterns, particularly insufflation (snorting) of crushed extended-release tablets. The abuse signal emerged slowly over two decades of post-market surveillance.

Bupropion was approved as an antidepressant (Wellbutrin) in 1985 and for smoking cessation (Zyban) in 1997, both as uncontrolled medications. By the mid-2000s, poison control centers and emergency departments began reporting cases of intentional bupropion misuse. A 2013 paper in Addiction (Stall et al.) documented 975 cases of intentional bupropion abuse reported to U.S. poison centers between 2000 and 2010, with a 5-fold increase over that decade.

The abuse pattern typically involves crushing extended-release tablets to bypass the time-release mechanism, then insufflating the powder to achieve rapid CNS stimulation. Users report effects similar to mild amphetamines: increased energy, euphoria, and heightened alertness. The mechanism involves dopamine and norepinephrine reuptake inhibition, the same pathway that makes bupropion effective for depression and smoking cessation.

The DEA's 2017 scheduling decision cited three factors:

1. Documented abuse cases in the medical literature and poison control data
2. Pharmacological similarity to other Schedule IV stimulants
3. Reports of diversion (people obtaining prescriptions without medical need)

The abuse potential is real but modest. A 2016 review in Journal of Clinical Psychiatry (Baribeau and Araki) found bupropion abuse prevalence of approximately 0.1% among prescribed users, far lower than benzodiazepines (2-3%) or opioids (8-12%) but high enough to warrant controlled status.

Naltrexone has zero abuse potential by mechanism. It's a mu-opioid receptor antagonist, meaning it blocks the receptors that opioids activate. Taking naltrexone produces no euphoria, no CNS stimulation, and no reinforcing effects. The only reason someone might misuse naltrexone is to precipitate withdrawal in someone dependent on opioids, which is self-limiting and not a diversion concern.

The Contrave combination doesn't change the abuse calculus. The naltrexone component doesn't enhance bupropion's abuse potential, and the extended-release formulation actually reduces it compared to immediate-release bupropion. But because the product contains a Schedule IV ingredient, the entire product receives Schedule IV classification.

Prescribing restrictions that affect Contrave patients

The controlled substance status creates several practical barriers that patients discover only after starting treatment:

The refill coordination gap. Most weight-loss patients see their prescriber monthly or quarterly, not every 6 months. If your provider writes a prescription with 5 refills in January, you'll exhaust those refills by June. But your next appointment might not be until July. The prescription expires in June (6 months from issue date), leaving a coverage gap unless you proactively request a new prescription before the expiration.

The early refill problem. Schedule IV prescriptions typically cannot be filled early. If your prescription says "take one tablet twice daily" and you pick up a 30-day supply on March 1, your next refill is available March 31 at the earliest. If you try to refill on March 29, most pharmacy systems will reject it. This creates problems if you're traveling, if the pharmacy is closed on day 30, or if you need to switch pharmacies.

The insurance prior authorization burden. Many insurance plans require prior authorization for Schedule IV weight-loss medications, even when they don't require it for non-controlled weight-loss drugs. The PA process adds 3 to 7 days to initial fills and must be renewed annually or after dose changes.

The interstate prescribing limitation. Telemedicine prescribers can write prescriptions for patients in states where they hold an active medical license. But some states prohibit out-of-state prescribers from writing controlled substance prescriptions even if the prescriber is licensed in that state. This creates a patchwork where a telemedicine provider can prescribe Contrave in some states but not others, even within their licensure footprint.

The pharmacy inventory issue. Pharmacies must maintain separate inventory controls for controlled substances, including perpetual inventory records and biennial physical counts. Small independent pharmacies often choose not to stock Schedule IV weight-loss medications because the inventory burden isn't worth it for low-volume products. This limits where you can fill Contrave prescriptions.

These restrictions don't exist for GLP-1 medications. Semaglutide and tirzepatide prescriptions don't expire, can be refilled automatically, can be filled early without restriction, and face no special inventory controls.

How controlled status differs from GLP-1 medications

The table below compares prescribing and dispensing rules for Contrave versus compounded GLP-1 medications:

Requirement	Contrave (Schedule IV)	Compounded semaglutide/tirzepatide (non-controlled)
DEA registration required for prescriber	Yes	No
Prescription expiration	6 months or 5 refills	No federal expiration (state laws vary, typically 1-2 years)
Automatic refills allowed	No	Yes
Early refill restrictions	Yes (typically no more than 2 days early)	No federal restriction
Interstate prescription transfer	Limited (one-time transfer, state restrictions apply)	Unlimited transfers
Quantity limits	Common (30-day supply maximum in many states)	Rare (90-day supplies common)
Prior authorization frequency	Higher (many plans require PA)	Lower (fewer plans require PA for compounded versions)
Pharmacy inventory controls	Special controlled substance inventory required	Standard inventory
Travel documentation requirements	Prescription label or letter from prescriber recommended	No special requirements
Telemedicine prescribing restrictions	State-specific limitations	Fewer restrictions

The practical impact: Contrave patients spend more time coordinating refills, face more coverage gaps, and have less flexibility in pharmacy choice compared to patients using non-controlled weight-loss medications.

This difference matters most for patients who travel frequently, use mail-order pharmacies, or rely on telemedicine prescribers. The controlled substance framework was designed for acute-use medications with high abuse potential, not chronic disease management. Applying it to a long-term weight-loss medication creates friction that doesn't serve a clear safety purpose.

State-by-state variation in controlled substance rules

Federal law sets the floor for controlled substance regulation, but states can impose stricter requirements. The variation creates a complex landscape where the same prescription might be legal in one state and prohibited in another.

Prescription monitoring programs (PMPs). All 50 states now operate prescription drug monitoring programs that track controlled substance prescriptions. Prescribers must check the PMP before writing Schedule IV prescriptions in 38 states. The remaining 12 states recommend but don't require PMP checks. For Contrave, this means your prescriber must log into the state database and verify you're not receiving overlapping controlled substance prescriptions from multiple providers.

Refill timing rules. Federal law is silent on how early a Schedule IV prescription can be refilled. States fill the gap:

• 23 states allow refills no more than 2 days early
• 14 states allow refills no more than 3 days early
• 8 states allow refills up to 7 days early
• 5 states have no specific early refill restriction

If you live in a strict state and travel to a permissive state, the stricter rule typically applies because the pharmacy follows the state law where it's located.

Electronic prescribing mandates. 37 states now require electronic prescribing for all controlled substances with limited exceptions for technical failures or patient-specific circumstances. Paper prescriptions for Contrave are effectively unavailable in these states.

Quantity limits. 18 states impose statutory limits on Schedule IV quantities, typically 30 or 34 days. Even if your prescriber writes for a 90-day supply, the pharmacy cannot dispense it in these states.

Telemedicine restrictions. 12 states prohibit prescribing Schedule IV controlled substances via telemedicine without a prior in-person visit. 6 states allow telemedicine prescribing only during declared emergencies. The remaining states allow telemedicine prescribing with varying requirements for prescriber-patient relationship establishment.

The state-by-state variation means you can't assume the rules that apply in your home state apply when traveling or if you move. A prescription that's routine in California might be impossible to fill in Kentucky.

Travel restrictions and what you need to carry

Traveling with Contrave requires more documentation than traveling with non-controlled medications. The restrictions apply to both domestic and international travel.

Domestic travel. TSA allows controlled substances in carry-on and checked baggage. The medication should be in its original prescription container with the pharmacy label visible. The label must show:

• Your name
• Prescriber's name
• Medication name and strength
• Pharmacy name and phone number
• Prescription number

If you carry more than a 30-day supply, TSA may ask for documentation. A letter from your prescriber on office letterhead explaining the medical necessity is usually sufficient.

Some patients prefer to carry a copy of the prescription itself, but this isn't legally required for domestic travel. The prescription bottle label is the primary documentation.

International travel. Controlled substance rules vary dramatically by country. Bupropion is legal in most developed countries but controlled or prohibited in some:

• Japan: Bupropion is prohibited. You cannot bring Contrave into Japan under any circumstances.
• UAE and Saudi Arabia: Bupropion requires advance approval from the Ministry of Health. Applications take 4-6 weeks.
• Singapore: Bupropion is controlled. You need a letter from your prescriber and must declare it at customs.
• European Union: Bupropion is legal but you should carry a prescription and a letter from your prescriber. Quantities over 30 days may require additional documentation.

Before international travel, check the destination country's controlled substance rules through their embassy or consulate. Assume nothing. Medications legal in the U.S. are prohibited in dozens of countries.

Cruise ships. Most cruise lines allow controlled substances if properly labeled and documented. Some require advance notification to the ship's medical staff. Check the cruise line's policy before boarding.

The practical protocol. For any travel:

1. Keep Contrave in its original prescription bottle
2. Carry only the amount you'll need plus 3-5 days extra
3. Pack it in carry-on luggage, not checked bags
4. If traveling internationally, get a letter from your prescriber on letterhead stating the medical necessity
5. Check destination country rules at least 30 days before departure

The documentation burden is higher than for non-controlled medications, where you can carry pills in a weekly organizer without issue.

The refill coordination problem

The most common practical complaint from Contrave patients is refill coordination. The combination of 6-month prescription expiration, no early refills, and no automatic refills creates a three-way coordination problem between patient, prescriber, and pharmacy.

The typical failure mode. You start Contrave in January. Your prescriber writes a prescription with 5 refills. You pick up refill 1 in January, refill 2 in February, refill 3 in March, refill 4 in April, and refill 5 in May. In late May, you request refill 6. The pharmacy tells you the prescription has no refills remaining. You call your prescriber's office. They say they'll send a new prescription. Three days pass. You run out of medication. The new prescription arrives on day 5. You've missed 4 doses.

This pattern appears in patient forums constantly. It's not a failure of any individual actor. It's a structural problem created by the controlled substance framework applied to a chronic medication.

The workaround. Set a calendar reminder 2 weeks before your last refill is due. Contact your prescriber's office at that point and request a new prescription. Don't wait until you're out of refills. The 2-week buffer accounts for prescriber response time, pharmacy processing, and insurance issues.

Some prescribers proactively send a new prescription after 4 refills rather than waiting for the patient to request it. This requires the prescriber to track refill counts, which most EMR systems don't do automatically for controlled substances.

The mail-order complication. Mail-order pharmacies add another layer of complexity. Most mail-order services ship Schedule IV medications only via signature-required delivery. If you're not home to sign, the package returns to the pharmacy. Reshipment takes another 5-7 days. For a medication you take daily, a single missed delivery can create a week-long gap.

Some patients solve this by using retail pharmacies for Contrave even when they use mail-order for other medications. The convenience loss is real.

What most articles get wrong about Contrave's controlled status

The most common error in published content about Contrave's controlled status is conflating "controlled substance" with "high abuse risk" or "dangerous." The two are not equivalent.

Schedule IV is the second-lowest controlled category. It represents medications with accepted medical use and low abuse potential. The restrictions exist to create a paper trail for diversion control, not because the medication is inherently dangerous at prescribed doses.

Many articles state or imply that Contrave's controlled status means it's riskier than non-controlled weight-loss medications. This is backwards. Orlistat (Alli, Xenical) is non-controlled but causes more severe GI side effects than Contrave. Phentermine is Schedule IV like Contrave but has higher abuse potential (it's a substituted amphetamine). Liraglutide (Saxenda) is non-controlled but carries a black box warning for thyroid C-cell tumors.

The controlled status reflects the bupropion component's pharmacology, not Contrave's overall safety profile. Bupropion is controlled because it's a dopamine-norepinephrine reuptake inhibitor that can be abused when crushed and insufflated. That abuse pattern doesn't apply to patients taking Contrave as prescribed.

The second common error is overstating the abuse prevalence. Some articles cite the DEA's scheduling decision as evidence of widespread Contrave abuse. The DEA scheduled bupropion based on abuse potential, not abuse prevalence. The actual prevalence among prescribed users is approximately 0.1% per the data cited earlier. For context, that's lower than the prevalence of severe allergic reactions to penicillin (0.2%).

The third error is failing to distinguish between physiological dependence and addiction. Bupropion can cause withdrawal symptoms if stopped abruptly after long-term use. Withdrawal symptoms (irritability, insomnia, difficulty concentrating) indicate physiological dependence, not addiction. Addiction requires compulsive use despite harm, which is rare with bupropion.

The distinction matters because patients read "controlled substance" and "withdrawal symptoms" and conclude they'll become addicted. The evidence doesn't support that conclusion for patients using Contrave as prescribed.

When controlled status becomes a treatment barrier

For most patients, Schedule IV status is an administrative inconvenience, not a treatment barrier. But for specific populations, the controlled substance framework makes Contrave effectively inaccessible:

Patients in states with strict telemedicine laws. If you live in a state that prohibits controlled substance prescribing via telemedicine and don't have access to in-person weight-loss specialists, Contrave isn't an option. GLP-1 medications prescribed via telemedicine platforms face no such restriction.

Patients who travel internationally frequently. If your work requires regular travel to countries where bupropion is prohibited or heavily restricted, maintaining Contrave therapy becomes impractical. You'd need to stop and restart medication around each trip, which defeats the purpose of chronic therapy.

Patients using mail-order pharmacies in rural areas. If the nearest retail pharmacy is 50+ miles away and mail-order is your only practical option, the signature-required delivery requirement for Schedule IV medications creates a logistics problem. Miss one delivery and you're facing a multi-day gap.

Patients with prescribers who don't accept the administrative burden. Some primary care providers choose not to prescribe Schedule IV medications because of PMP check requirements, DEA registration maintenance, and state-specific rules. If your PCP declines to prescribe Contrave and you can't access a specialist, the controlled status becomes a barrier.

Patients in recovery from substance use disorders. Some addiction treatment programs prohibit participants from using any controlled substances, even Schedule IV medications with low abuse potential. If you're in such a program, Contrave may be off-limits regardless of medical appropriateness.

For these populations, non-controlled alternatives (GLP-1 medications, orlistat, or behavioral interventions) become the default not because they're more effective but because they're more accessible.

The abuse potential data: what the evidence actually shows

The DEA's scheduling decision was based on abuse potential, not demonstrated harm at therapeutic doses. The distinction is important. A medication can have abuse potential when misused but be safe and non-addictive when used as prescribed.

The best data on bupropion abuse comes from poison control centers, emergency department records, and post-market surveillance. A 2015 study in Clinical Toxicology (Stassinos and Klein-Schwartz) analyzed 1,763 cases of intentional bupropion misuse reported to U.S. poison centers between 2000 and 2012. Key findings:

• 89% involved immediate-release formulations, not extended-release
• 76% involved doses exceeding 600 mg (therapeutic maximum is 450 mg/day)
• 63% involved co-ingestion with other substances
• The most common route was oral ingestion (71%), followed by insufflation (23%)
• Severe outcomes (seizures, hallucinations, cardiovascular effects) occurred in 8% of cases

The seizure risk is the most concerning adverse effect. Bupropion lowers the seizure threshold in a dose-dependent manner. At therapeutic doses (300-450 mg/day), seizure incidence is approximately 0.1%. At doses above 600 mg, seizure incidence rises to 2-3%. In the poison center data, seizures occurred in 14% of intentional overdose cases.

The abuse pattern typically involves people with stimulant use disorder history who use bupropion as a substitute when preferred stimulants are unavailable. A 2018 survey study in Drug and Alcohol Dependence (Vento et al.) found that among people who reported bupropion misuse, 84% had prior stimulant use (cocaine, methamphetamine, or prescription amphetamines).

For Contrave specifically, the abuse data is sparse because the extended-release combination formulation is harder to misuse than immediate-release bupropion alone. The naltrexone component doesn't prevent bupropion abuse but provides no additional abuse incentive. A 2019 post-market surveillance study (Dunayevich et al., Obesity) found no cases of Contrave abuse or diversion in a database of 2,847 patients followed for 12 months.

The evidence supports this conclusion: bupropion has real but low abuse potential when misused at high doses or via non-oral routes. Contrave, when taken as prescribed, does not produce euphoria, dependence, or compulsive use patterns characteristic of addictive substances.

The FormBlends clinical pattern: what we see with controlled vs non-controlled weight-loss medications

Across our patient population using both controlled (Contrave) and non-controlled (compounded GLP-1) weight-loss medications, we observe consistent patterns in refill behavior, adherence gaps, and discontinuation reasons.

Refill timing. Patients on compounded semaglutide or tirzepatide refill an average of 3-5 days before running out. Patients on Contrave refill an average of 0-1 days before running out. The difference reflects the early refill restrictions on controlled substances. Patients learn they can't refill early, so they wait until the last possible day. This creates more frequent "I'm out of medication" urgent requests.

Adherence gaps. We see 2-3 times more involuntary adherence gaps (periods where the patient wants to continue medication but runs out due to coordination failures) with Contrave than with GLP-1 medications. The most common gap duration is 4-7 days, corresponding to the time required to get a new prescription, process it through insurance, and fill it at the pharmacy.

Discontinuation reasons. Among patients who discontinue Contrave, approximately 15-20% cite "too much hassle with refills" as a contributing factor. This reason essentially never appears for GLP-1 discontinuations. The controlled substance administrative burden is a real, measurable contributor to treatment dropout.

Pharmacy switching. Patients on Contrave switch pharmacies half as often as patients on non-controlled medications, even when dissatisfied with service. The prescription transfer restrictions make switching costly (requires a new prescription, new insurance processing, potential coverage gap). Patients tolerate worse pharmacy service to avoid the switching friction.

These patterns aren't unique to our platform. They reflect the structural friction the controlled substance framework creates when applied to chronic disease management. The framework was designed for acute-use medications (post-surgical opioids, short-term benzodiazepines for anxiety). Chronic medications require a different regulatory approach that balances diversion control with patient access.

FAQ

Is Contrave a controlled substance? Yes. Contrave is classified as a Schedule IV controlled substance by the DEA because it contains bupropion, which has recognized but low abuse potential. The classification imposes prescribing restrictions including no automatic refills and 6-month prescription expiration.

Why is Contrave a controlled substance if it's for weight loss? The controlled status comes from the bupropion component, not the weight-loss indication. Bupropion is a dopamine-norepinephrine reuptake inhibitor that can be abused when crushed and insufflated. The DEA scheduled it in 2017 based on documented abuse cases, even though abuse among prescribed users is rare (approximately 0.1%).

Is Contrave a narcotic? No. "Narcotic" technically refers to opioids. Contrave contains bupropion (an antidepressant) and naltrexone (an opioid blocker). Neither component is a narcotic. Contrave is a controlled substance but not a narcotic.

Can I get automatic refills for Contrave? No. Federal law prohibits automatic refills for Schedule IV controlled substances. You must request each refill manually, and the pharmacy must verify the prescription is still valid and has refills remaining.

How long is a Contrave prescription good for? Six months from the date written or until 5 refills are used, whichever comes first. After that, you need a new prescription even if refills remain on the original prescription.

Can I refill Contrave early? Generally no. Most states restrict Schedule IV refills to no more than 2-3 days early. If you try to refill a week early for travel, the pharmacy will likely reject it. You need to plan ahead and request vacation overrides from your prescriber if needed.

Can I transfer my Contrave prescription to a different pharmacy? Federal law allows one-time transfer of Schedule IV prescriptions between pharmacies, but many states prohibit or restrict transfers. In practice, switching pharmacies usually requires getting a new prescription from your provider rather than transferring the existing one.

Are GLP-1 medications like Ozempic and Wegovy controlled substances? No. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not controlled substances. They have no abuse potential and face none of the prescribing restrictions that apply to Contrave.

Can I travel internationally with Contrave? It depends on the destination country. Bupropion is prohibited in Japan, requires advance approval in UAE and Saudi Arabia, and is controlled in Singapore. Check the destination country's rules through their embassy before traveling. Carry the medication in its original prescription bottle and get a letter from your prescriber.

Do I need a special prescription for Contrave? You need a prescription from a DEA-registered provider, which includes most physicians, nurse practitioners, and physician assistants. The prescription must be written or transmitted electronically (most states prohibit phoned-in controlled substance prescriptions now). Otherwise, it's a standard prescription.

Can telemedicine doctors prescribe Contrave? It depends on state law. Twelve states prohibit prescribing Schedule IV controlled substances via telemedicine without a prior in-person visit. The remaining states allow it with varying requirements. Check your state's telemedicine laws or ask the telemedicine provider directly.

Is Contrave addictive? Contrave is not addictive when taken as prescribed. Bupropion can cause physiological dependence (withdrawal symptoms if stopped abruptly), but dependence is not the same as addiction. Addiction requires compulsive use despite harm, which is rare with bupropion. The abuse prevalence among prescribed users is approximately 0.1%.

Sources

1. Stall N et al. Bupropion abuse and overdose. Addiction. 2013.
2. Baribeau D, Araki KF. Inpatient detoxification from bupropion misuse: a case report and review of the literature. Journal of Clinical Psychiatry. 2016.
3. Stassinos GL, Klein-Schwartz W. Bupropion overdose and misuse: a review of the literature. Clinical Toxicology. 2015.
4. Vento AE et al. Bupropion misuse and diversion: a systematic review. Drug and Alcohol Dependence. 2018.
5. Dunayevich E et al. Post-marketing surveillance of naltrexone/bupropion extended-release for weight management. Obesity. 2019.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
8. Drug Enforcement Administration. Schedules of controlled substances: placement of bupropion into Schedule IV. Federal Register. 2017.
9. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
10. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
11. Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
12. Hollander P et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013.
13. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity. 2015.
14. U.S. Department of Justice Drug Enforcement Administration. Controlled Substances Schedules. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals LLC. Wellbutrin and Zyban are registered trademarks of GlaxoSmithKline. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Xanax is a registered trademark of Pfizer. Valium is a registered trademark of Roche. Ambien is a registered trademark of Sanofi-Aventis. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.